Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa

NCT02907853 | Completed

• 1 other identifier: R21CMinSA
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.

Conditions

Methamphetamine Abuse

Outcome Measures

Primary Outcomes (2)

• Responses to Contingency Management

  urine samples documenting methamphetamine abstinence

  8 weeks

• fMRI Measures

  measures of resting state connectivity

  Change b/w baseline and 8 Weeks

Secondary Outcomes (4)

• Stop Signal Task

  Change b/w baseline and 8 Weeks

• Continuous Performance Task

  Change b/w baseline and 8 Weeks

• Stroop

  Change b/w baseline and 8 Weeks

• Balloon Analog Risk Task

  Change b/w baseline and 8 Weeks

Study Arms (1)

Contingency Management

EXPERIMENTAL

In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.

Behavioral: Contingency Management

Interventions

Contingency Management BEHAVIORAL

as described above

Contingency Management

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• provide voluntary informed consent
• meet DSM-5 criteria for MA or amphetamine use disorder
• provide at least one urine sample positive for MA/amphetamine metabolites during screening (i.e. prior to the commencement of the study).
• aged 18-45
• right-handed
• English-speaking

You may not qualify if:

• currently receiving treatment for stimulant addiction or needing more intensive treatment than outpatient care
• meet DSM-5 criteria for substance use disorder other than nicotine
• unable to attend 4+ visits during the 2-week screening period or to complete measures
• Physical or mental illness that would require intervention that would alter imaging or that would interfere with safe study participation
• pregnant, claustrophobic, or have metal prostheses, cardiac pacemakers, or metal clips that are incompatible with the scanner
• HIV positive status
• unable to comprehend written or spoken English
• currently taking psychiatric medication

Sponsors & Collaborators

• University of California, Los Angeles: lead
• University of Cape Town: collaborator

Study Sites (1)

Department of Psychiatry at Groote Schuur Hospital

Cape Town, 7925, South Africa

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: September 13, 2016
• First Posted: September 20, 2016
• Study Start: September 1, 2015
• Primary Completion: February 15, 2018
• Study Completion: February 15, 2018
• Last Updated: May 10, 2019

Record last verified: 2019-05

Data Sharing

• IPD Sharing: Will share

Locations

ZA (1)